Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes today touted 4-year data from a large registry study showing that its Attune knee implant had a lower revision rate than the overall rate for total knee replacement.
The study examined data from 10,605 Attune implantations in Britain’s National Joint Registry for England, Wales, Northern Ireland & the Isle of Man, finding that the revision rate for Attune was 1.3% at 4 years, compared with the registry’s 1.9% average. Just 46 of the Attune knee procedures required revision, DePuy Synthes said.
“This most recent analysis adds to the body of evidence on the positive performance of the Attune knee,” franchise medical director Joshua Bridgens said in prepared remarks. “The information and data in this analysis, such as reasons for revision and preliminary findings on patient-reported outcomes, continue to validate the design principles and our expectations for the clinical performance of the Attune knee.”
The results were presented at the annual meeting of the European Federation of the National Assocs. of Orthopaedics & Traumatology Congress in Vienna, DePuy Synthes said.
In March, the Warsaw, Ind.-based company touted the economic benefits of the Attune device, based on data from a variety of sources including the U.K.’s NJR.
Last month, DePuy Synthes said it acquired 3D printing technology assets from Tissue Regeneration Systems for an undisclosed amount, saying it plans to use the technology to create patient-specific, bioresorbable implants for correcting orthopedic and craniomaxillofacial deformities and injuries.